Sulfotransferase genetic variation: From cancer risk to treatment response

Drug Metabolism Reviews

Volumn 45, Issue 4, 2013, Pages 415-422

  Daniels, Jaclyn ^a   Kadlubar, Susan ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Breast cancer; Cancer survival; Environmental exposures; Gene gene interactions; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; MICRORNA; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1C; SULFOTRANSFERASE 1C2; SULFOTRANSFERASE 1E1; TAMOXIFEN; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ASIAN; BLADDER CANCER; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; COPY NUMBER VARIATION; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ETHNICITY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG CANCER; OVARY CANCER; PHENOTYPE; POSTMENOPAUSE; PROMOTER REGION; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK;

EID: 84887389442     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2013.835621     Document Type: Review

References (81)

1. Anderson RJ, Jackson BL. (1984). Human platelet phenol sulfotransferase: stability of two forms of the enzyme with time and presence of a racial difference. Clin Chim Acta 138:185-196. (Pubitemid 14128254)
2. Arlt VM, Glatt H, Muckel E, et al. (2002). Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase. Carcinogenesis 23:1937-1945. (Pubitemid 35355944)
3. Arlt VM, Stiborova M, Henderson CJ, et al. (2005). Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65:2644-2652. (Pubitemid 40490063)
4. Arslan S. (2010). Genetic polymorphisms of sulfotransferases (SULT1A1 and SULT1A2) in a Turkish population. Biochem Genet 48:987-994.
5. Arslan S, Silig Y, Pinarbasi H. (2009). An investigation of the relationship between SULT1A1 Arg(213)His polymorphism and lung cancer susceptibility in a Turkish population. Cell Biochem Funct 27:211-215.
6. Arslan S, Silig Y, Pinarbasi H. (2011). Sulfotransferase 1A1 Arg(213)His polymorphism and prostate cancer risk. Exp Ther Med 2:1159-1162.
7. Borque A, Del Amo J, Esteban LM, et al. (2013). Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU Int 111: 549-558.
8. Chou HC, Lang NP, Kadlubar FF. (1995). Metabolic activation of N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(s). Cancer Res 55:525-529.
9. Cleary SP, Cotterchio M, Shi E, et al. (2010). Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol 172:1000-1014.
10. Cotterchio M, Boucher BA, Manno M, et al. (2008). Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17:3098-3107.
11. Coughtrie MW, Johnston LE. (2001). Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance. Drug Metab Dispos 29:522-528. (Pubitemid 32275528)
12. Deeken JF, Cormier T, Price DK, et al. (2010). A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.Pharmacogenomics J 10:191-199.
13. Dumas I, Diorio C. (2011). Estrogen pathway polymorphisms and mammographic density. Anticancer Res 31:4369-4386.
14. Edavana VK, Dhakal IB, Yu X, et al. (2012). Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics. Drug Metab Dispos 40: 1210-1215.
15. Edavana VK, Yu X, Dhakal IB, et al. (2011). Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1.Pharmgenomics Pers Med 4:137-145.
16. Falany CN, Wheeler J, Oh TS, Falany JL. (1994). Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol 48:369-375. (Pubitemid 24128602)
17. Falany JL, Azziz R, Falany CN. (1998). Identification and characterization of cytosolic sulfotransferases in normal human endometrium.Chem Biol Interact 109:329-339. (Pubitemid 28161124)
18. Falany JL, Falany CN. (1996a). Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines.Cancer Res 56:1551-1555. (Pubitemid 26104018)
19. Falany JL, Falany CN. (1996b). Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone.Endocrinology 137:1395-1401. (Pubitemid 26095258)
20. Fan C, Jin M, Chen K, et al. (2007). Case-only study of interactions between metabolic enzymes and smoking in colorectal cancer. BMC Cancer 7:115-122.
21. Ferlin A, Ganz F, Pengo M, et al. (2010). Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr Relat Cancer 17:17-25.
22. Figueroa JD, Malats N, Garcia-Closas M, et al. (2008). Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes.Carcinogenesis 29:1955-1962.
23. Fortuny J, Kogevinas M, Garcia-Closas M, et al. (2006). Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 15:1696-1702. (Pubitemid 44497106)
24. Gjerde J, Hauglid M, Breilid H, et al. (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:56-61.
25. Grabinski JL, Smith LS, Chisholm GB, et al. (2006). Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Res Treat 95:13-16. (Pubitemid 43228077)
26. Gulyaeva LF, Mikhailova ON, Pustyinyak VO, et al. (2008).Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Biol 617:359-366.
27. Hebbring SJ, Adjei AA, Baer JL, et al. (2007). Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet 16:463-470. (Pubitemid 46522610)
28. Hirata H, Hinoda Y, Okayama N, et al. (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 112:1964-1973. (Pubitemid 351574072)
29. Huang SK, Chiu AW, Pu YS, et al. (2009). Arsenic methylation capability, myeloperoxidase and sulfotransferase genetic polymorphisms, and the stage and grade of urothelial carcinoma. Urol Int 82: 227-234.
30. Ihsan R, Chauhan PS, Mishra AK, et al. (2011). Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLoS One 6:e29431-e29441.
31. Jakoby WB, Ziegler DM. (1990). The enzymes of detoxication. J Biol Chem 265:20715-20718. (Pubitemid 120014066)
32. Jiang Y, Zhou L, Yan T, et al. (2010). Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue. J Exp Clin Cancer Res 29:101-110.
33. Kellen E, Zeegers M, Paulussen A, et al. (2006). Fruit consumption reduces the effect of smoking on bladder cancer risk. The Belgian case control study on bladder cancer. Int J Cancer 118:2572-2578.
34. Kellen E, Zeegers M, Paulussen A, et al. (2007). Does occupational exposure to PAHs, diesel and aromatic amines interact with smoking and metabolic genetic polymorphisms to increase the risk on bladder cancer; The Belgian case control study on bladder cancer risk.Cancer Lett 245:51-60. (Pubitemid 46001500)
35. Kester MH, Kaptein E, Roest TJ, et al. (1999). Characterization of human iodothyronine sulfotransferases. J Clin Endocrinol Metab 84: 1357-1364. (Pubitemid 30644400)
36. Khvostova EP, Pustylnyak VO, Gulyaeva LF. (2012). Genetic polymorphism of estrogen metabolizing enzymes in Siberian women with breast cancer. Genet Test Mol Biomarkers 16:167-173
37. Kilbourne ED. (1973). The molecular epidemiology of influenza.J Infect Dis 127:478-487.
38. Knechtel G, Hofmann G, Gerger A, et al. (2010). Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J Cancer Res Clin Oncol 136: 1813-1819.
39. Koike H, Nakazato H, Ohtake N, et al. (2008). Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population. Int Urol Nephrol 40:947-951.
40. Kotnis A, Kannan S, Sarin R, Mulherkar R. (2008). Case-control study and meta-analysis of SULT1A1 Arg213His polymorphism for gene, ethnicity and environment interaction for cancer risk. Br J Cancer 99: 1340-1347.
41. Koutros S, Berndt SI, Sinha R, et al. (2009). Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res 69:1877-1884.
42. Lee H, Wang Q, Yang F, et al. (2012). SULT1A1 Arg213His polymorphism, smoked meat, and breast cancer risk: a case-control study and meta-analysis. DNA Cell Biol 31:688-699.
43. Li X, Anderson RJ. (1999). Sulfation of iodothyronines by recombinant human liver steroid sulfotransferases. Biochem Biophys Res Commun 263:632-639. (Pubitemid 29490677)
44. Liao SG, Liu L, Zhang YY, et al. (2012). SULT1A1 Arg213His polymorphism and lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev 13:579-583.
45. Lilla C, Risch A, Verla-Tebit E, et al. (2007). SULT1A1 genotype and susceptibility to colorectal cancer. Int J Cancer 120:201-206. (Pubitemid 44901937)
46. Lin ZN, Lin YC, Zhang X, et al. (2012). Differential promoter activities of functional haplotypes in the 50-flanking region of human sulfotransferase 1A1. J Biochem Mol Toxicol 26:422-428.
47. Mercer KE, Apostolov EO, Da Costa GG, et al. (2010). Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis. Int J Mol Epidemiol Genet 1:92-103.
48. Monzo M, Brunet S, Urbano-Ispizua A, et al. (2006). Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 107:4871-4879. (Pubitemid 43882640)
49. Moyer AM, Suman VJ, Weinshilboum RM, et al. (2011). SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics 12:1535-1543.
50. Ning B, Nowell S, Sweeney C, et al. (2005). Common genetic polymorphisms in the 50-flanking region of the SULT1A1 gene: haplotypes and their association with platelet enzymatic activity.Pharmacogenet Genomics 15:465-473. (Pubitemid 41017595)
51. Nishiyama T, Ogura K, Nakano H, et al. (2002). Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet 17:221-228.
52. Nowell S, Ratnasinghe DL, Ambrosone CB, et al. (2004). Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 13:270-276. (Pubitemid 38222559)
53. Nowell S, Sweeney C, Winters M, et al. (2002). Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94:1635-1640. (Pubitemid 35378729)
54. O'Mara TA, Ferguson K, Fahey P, et al. (2011). CHEK2, MGMT, SULT1E1 and SULT1A1 polymorphisms and endometrial cancer risk.Twin Res Hum Genet 14:328-332.
55. Ozawa S, Tang YM, Yamazoe Y, et al. (1998). Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact 109:237-248. (Pubitemid 28161116)
56. Pachouri SS, Sobti RC, Kaur P, et al. (2006). Impact of polymorphism in sulfotransferase gene on the risk of lung cancer. Cancer Genet Cytogenet 171:39-43. (Pubitemid 44635751)
57. Pai TG, Sugahara T, Suiko M, et al. (2002). Differential xenoestrogensulfating activities of the human cytosolic sulfotransferases: molecular cloning, expression, and purification of human SULT2B1a and SULT2B1b sulfotransferases. Biochim Biophys Acta 1573:165-170. (Pubitemid 35217937)
58. Pai TG, Suiko M, Sakakibara Y, Liu MC. (2001). Sulfation of flavonoids and other phenolic dietary compounds by the human cytosolic sulfotransferases. Biochem Biophys Res Commun 285:1175-1179. (Pubitemid 32912904)
59. Raftogianis RB, Her C, Weinshilboum RM. (1996). Human phenol sulfotransferase pharmacogenetics: STP1 gene cloning and structural characterization. Pharmacogenetics 6:473-487.
60. Raftogianis RB, Wood TC, Otterness DM, et al. (1997). Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298-304. (Pubitemid 27480360)
61. Reding KW, Chen C, Lowe K, et al. (2012). Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes Control 23:671-681.
62. Sakakibara Y, Yanagisawa K, Katafuchi J, et al. (1998). Molecular cloning, expression, and characterization of novel human SULT1C sulfotransferases that catalyze the sulfonation of N-hydroxy-2- acetylaminofluorene. J Biol Chem 273:33929-33935.
63. Serrano D, Lazzeroni M, Zambon CF, et al. (2011). Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.Pharmacogenomics J 11:100-107.
64. Spink BC, Katz BH, Hussain MM, et al. (2000). SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells.Carcinogenesis 21:1947-1957.
65. Sugahara T, Liu CC, Pai TG, et al. (2003). Sulfation of hydroxychlorobiphenyls.Molecular cloning, expression, and functional characterization of zebrafish SULT1 sulfotransferases. Eur J Biochem 270: 2404-2411. (Pubitemid 36645358)
66. Sun Y, Zang Z, Xu X, et al. (2011). The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23 445 subjects. Breast Cancer Res Treat 125:215-219.
67. Syamala VS, Syamala V, Sheeja VR, et al. (2010). Possible risk modification by polymorphisms of estrogen metabolizing genes in familial breast cancer susceptibility in an Indian population. Cancer Invest 28:304-311.
68. Tamaki Y, Arai T, Sugimura H, et al. (2011). Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet 26: 516-522.
69. Tengstrom M, Mannermaa A, Kosma VM, et al. (2012). SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer BMC Cancer 12:257-264.
70. Udler MS, Azzato EM, Healey CS, et al. (2009). Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer 125: 2687-2696.
71. Visser TJ, Kaptein E, Glatt H, et al. (1998). Characterization of thyroid hormone sulfotransferases. Chem Biol Interact 109:279-291. (Pubitemid 28161120)
72. Wang YH, Juang GD, Hwang TI, et al. (2008a). Genetic polymorphism of sulfotransferase 1A1, cigarette smoking, hazardous chemical exposure and urothelial cancer risk in a Taiwanese population. Int J Urol 15:1029-1034.
73. Wang YH, Lee YH, Tseng PT, et al. (2008b). Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol 134:203-209.
74. Wang Z, Fu Y, Tang C, et al. (2010). SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8454 cases and 11 800 controls. Breast Cancer Res Treat 122:193-198.
75. Wegman P, Elingarami S, Carstensen J, et al. (2007). Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9: R7-R15.
76. Wegman P, Vainikka L, Stal O, et al. (2005). Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7:R284-R290.
77. Yasuda S, Idell S, Fu J, et al. (2007). Cigarette smoke toxicants as substrates and inhibitors for human cytosolic SULTs. Toxicol Appl Pharmacol 221:13-20. (Pubitemid 46702277)
78. Yong M, Schwartz SM, Atkinson C, et al. (2010). Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States. Cancer Epidemiol Biomarkers Prev 19:537-546.
79. Yu X, Dhakal IB, Beggs M, et al. (2010). Functional genetic variants in the 30-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci 118:391-403.
80. Zhang C, Li JP, Lv GQ, et al. (2011). Lack of association of SULT1A1 R213H polymorphism with colorectal cancer: a meta-analysis. PLoS One 6:e19127-e19132.
81. Zhang L, Huang M, Blair IA, Penning TM. (2012). Detoxication of benzo[a]pyrene-7,8-dione by sulfotransferases (SULTs) in human lung cells. J Biol Chem 287:29909-29920.